Free Trial
→ $100 Trillion “AI Metal” Found in American Ghost Town (From Brownstone Research) (Ad)tc pixel
NASDAQ:GNPX

GENPREX 11/14/2023 Earnings Report

GENPREX logo
$0.25 +0.04 (+19.72%)
Closing price 04:00 PM Eastern
Extended Trading
$0.24 -0.01 (-4.84%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

GENPREX EPS Results

Actual EPS
-$5.20
Consensus EPS
-$4.40
Beat/Miss
Missed by -$0.80
One Year Ago EPS
N/A

GENPREX Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GENPREX Announcement Details

Quarter
Date
11/14/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

GENPREX's next earnings date is estimated for Tuesday, November 11, 2025, based on past reporting schedules.

Conference Call Resources

GENPREX Earnings Headlines

Genprex Stockholders Approve Key Proposals at Annual Meeting
September 3, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/GNPX/pressreleases/34206302/genprex-stockholders-approve-key-proposals-at-annual-meeting/
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences
September 2, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-to-present-and-participate-at-upcoming-september-investor-and-industry-conferences-302542573.html
Nvidia Times 1,000,000
Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 trillion calculations per second. Elon Musk and Nvidia’s Jensen Huang are now teaming up to deploy one million of these chips inside what could become the most advanced AI machine on the planet. But according to James Altucher, the real opportunity isn’t in Tesla or Nvidia. He’s uncovered a little-known company that Musk, Nvidia, and even 98% of the Fortune 500 already rely on to make AI 2.0 possible. Nvidia’s CEO has even called this company “essential” to their expansion.tc pixel
September 10 at 2:00 AM  |  Paradigm Press (Ad)
Genprex receives notice of allowance for multiple patents for Reqorsa
August 18, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/genprex-receives-notice-of-allowance-for-multiple-patents-for-reqorsa/ar-AA1KK2QK
Genprex Secures Patent Allowances for Gene Therapy
August 18, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genprex-secures-patent-allowances-for-gene-therapy?utm_source=marketbeat.com&utm_medium=referral
Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers
August 18, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-receives-notice-of-allowance-for-multiple-patents-for-reqorsa-gene-therapy-with-pd-l1-and-pd-1-antibodies-to-treat-cancers-302531812.html
See More GENPREX Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GENPREX? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GENPREX and other key companies, straight to your email.

About GENPREX

GENPREX (NASDAQ:GNPX), Inc. is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes. This preclinical program seeks to deliver genes that support insulin production and glucose regulation, laying the groundwork for future clinical development in metabolic diseases. By leveraging its gene delivery platform, the company aims to expand its pipeline into other oncology and metabolic indications over time.

Headquartered in Austin, Texas, Genprex operates under a management team with deep experience in gene therapy research and biopharmaceutical development. The company collaborates with leading academic and clinical research centers to conduct its studies, ensuring rigorous trial design and patient enrollment. Through these partnerships, Genprex seeks to translate cutting-edge genetic science into transformative therapies for patients with high-unmet medical needs.

View GENPREX Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles